Definium Therapeutics (NASDAQ:DFTX) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Definium Therapeutics (NASDAQ:DFTX) posted its quarterly earnings data on Thursday. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02), FiscalAI reports.

Here are the key takeaways from Definium Therapeutics’ conference call:

• Upcoming catalysts: Company expects three Phase 3 readouts in 2026 with Emerge (MDD) top-line in late Q2 2026, Voyage (GAD) in early Q3, and Panorama in H2 — plus Ascend dosing beginning in early Q2.
• Voyage completed a blinded sample-size re-estimation with no increase required; observed lower variability (SD ~6.7 vs planned 10) and lower non-evaluable rate, implying substantially higher power to detect the prespecified treatment effect.
• Strong balance sheet: year-end cash, equivalents and investments of $411.6M, which management says should fund operations into 2028 and supports pre-commercial investments and launch prep.
• Pipeline diversification: First participant dosed in Phase 2a of DT-402 (R‑MDMA) for autism spectrum disorder with initial data expected later in 2026, adding an earlier-stage program beyond DT120 ODT.
• Rising burn and loss: 2025 net loss widened to $183.8M (from $108.7M) driven by higher R&D and G&A spend, reflecting accelerated development and commercialization spending.

Definium Therapeutics Price Performance

Shares of DFTX traded down $0.33 during mid-day trading on Thursday, reaching $17.29. The stock had a trading volume of 1,123,415 shares, compared to its average volume of 1,836,327. The business has a fifty day moving average of $15.47 and a 200 day moving average of $12.72. The company has a debt-to-equity ratio of 0.31, a quick ratio of 3.30 and a current ratio of 3.30. The firm has a market cap of $1.70 billion, a price-to-earnings ratio of -8.48 and a beta of 2.57. Definium Therapeutics has a 12 month low of $4.70 and a 12 month high of $18.70.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on DFTX shares. Needham & Company LLC reaffirmed a “buy” rating on shares of Definium Therapeutics in a research report on Monday, January 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Thursday, January 22nd. Canaccord Genuity Group lifted their price target on shares of Definium Therapeutics from $16.00 to $25.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Chardan Capital raised shares of Definium Therapeutics to a “strong-buy” rating in a research report on Wednesday, November 19th. Finally, Royal Bank Of Canada raised their target price on Definium Therapeutics from $20.00 to $36.00 and gave the stock an “outperform” rating in a report on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Definium Therapeutics has a consensus rating of “Buy” and an average target price of $34.20.

Insider Activity at Definium Therapeutics

In other Definium Therapeutics news, CEO Robert Barrow sold 25,791 shares of the firm’s stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $13.15, for a total transaction of $339,151.65. Following the sale, the chief executive officer directly owned 778,477 shares of the company’s stock, valued at $10,236,972.55. This trade represents a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mark Sullivan sold 11,276 shares of the business’s stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $148,279.40. Following the completion of the transaction, the insider owned 282,576 shares in the company, valued at $3,715,874.40. The trade was a 3.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 42,667 shares of company stock worth $561,071. 2.26% of the stock is owned by corporate insiders.

Institutional Trading of Definium Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Commodore Capital LP grew its holdings in Definium Therapeutics by 10.5% during the 2nd quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock valued at $32,450,000 after buying an additional 475,000 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Definium Therapeutics by 11.0% in the third quarter. Vanguard Group Inc. now owns 2,012,874 shares of the company’s stock worth $23,732,000 after buying an additional 198,878 shares in the last quarter. UBS Group AG boosted its position in shares of Definium Therapeutics by 7.3% during the third quarter. UBS Group AG now owns 551,809 shares of the company’s stock worth $6,506,000 after acquiring an additional 37,364 shares during the last quarter. Orbimed Advisors LLC purchased a new position in Definium Therapeutics during the third quarter valued at $4,337,000. Finally, Millennium Management LLC increased its holdings in Definium Therapeutics by 62.6% in the 3rd quarter. Millennium Management LLC now owns 298,205 shares of the company’s stock valued at $3,516,000 after acquiring an additional 114,805 shares during the last quarter. Institutional investors own 27.91% of the company’s stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.